A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY

Sponsor:

Roche Pharmaceuticals

Sponsor Study ID:

CO44657

CTO #:

104139

NCT Number:

NCT06065748

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast

Study Objectives:

To evaluate the efficacy of Giredestrant compared with fulvestrant (both combined with CDK4/6i) in the ESR1m subgroup and FAS.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)